Evidence map›Paper›PMID 41716398›Full record

ArticleFrontiers in immunology2026

CNNeoPP: a large language model-enhanced deep learning pipeline for personalized neoantigen prediction and liquid biopsy applications.

Yu Cai, Rui Chen, Mingming Song, Lei Wang, Zirong Huo, Dongyan Yang, Sitong Zhang, Shenghan Gao, Seungyong Hwang, Ling Bai and 3 more

Abstract read
In one paragraph

Article in Frontiers in immunology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 6 papers.

0numbers the graph read from it
0cells of the map it votes in
6citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

6 citing papers in PubMed.

  1. Leveraging Artificial Intelligence and Large Language Models for Cancer Immunotherapy.Advanced science (Weinheim, Baden-Wurttemberg, Germany) · 2026
    Review
  2. Review
  3. Review
  4. Review
  5. Review
  6. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

13 authors.

Yu Cai *College of Life Sciences, Northwest University, Xi'an, Shaanxi, China.
Rui Chen *College of Life Sciences, Northwest University, Xi'an, Shaanxi, China.
Mingming SongCollege of Life Sciences, Northwest University, Xi'an, Shaanxi, China.
Lei WangInstitute of Nuclear and New Energy Technology, Tsinghua University, Beijing, China.
Zirong HuoCollege of Life Sciences, Northwest University, Xi'an, Shaanxi, China.
Dongyan YangCollege of Life Sciences, Northwest University, Xi'an, Shaanxi, China.
Sitong ZhangCollege of Life Sciences, Northwest University, Xi'an, Shaanxi, China.
Shenghan GaoDepartment of Thyroid Breast Surgery, Xi'an NO.3 Hospital, the Affiliated Hospital of Northwest University, Xi'an, Shaanxi, China.
Seungyong HwangDepartment of Statistics and Research Institute of Applied Statistics, Chonbuk National University, Jeonju, Jeonbuk-do, Republic of Korea.
Ling BaiDepartment of Ophthalmology, The Second Affiliated Hospital of Xi'an Jiaotong University, Xi'an, Shaanxi, China.
Yonggang LvDepartment of Thyroid Breast Surgery, Xi'an NO.3 Hospital, the Affiliated Hospital of Northwest University, Xi'an, Shaanxi, China.
Yali CuiCollege of Life Sciences, Northwest University, Xi'an, Shaanxi, China.
Xi ZhangDepartment of Ophthalmology, The Second Affiliated Hospital of Xi'an Jiaotong University, Xi'an, Shaanxi, China.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Neoantigens have emerged as promising targets for personalized cancer immunotherapy. However, accurate identification of immunogenic neoantigens remains a challenge due to limitations in existing predictive models. Here, we present CNNeo, a novel deep learning-based neoantigen prediction model, and CNNeoPP, an integrated computational pipeline for neoantigen discovery. CNNeo employs large language model-derived sequence representations and multi-modal feature integration, demonstrating superior predictive performance compared to existing tools. CNNeoPP was rigorously validated using independent datasets, including the TESLA dataset, and experimental validation via ELISpot T-cell assays. Additionally, we conducted a proof-of-concept study utilizing plasma cell-free DNA to explore the feasibility of non-invasive neoantigen prediction. We found that increased sequencing depth enhances neoantigen detectability, further amplified by the prioritization strategy of CNNeoPP. CNNeoDB, a publicly accessible database was developed compiling neoantigen data from multiple sources. This study establishes robust tools for neoantigen prediction, with implications for optimizing cancer immunotherapy and liquid biopsy-based tumor monitoring. CNNeoPP is available at https://github.com/AaronChen007/neoantigen.

Indexed as

Antigens, NeoplasmDeep LearningNeoplasmsComputational BiologyHumansImmunotherapyLarge Language ModelsLiquid BiopsyPrecision MedicinePrediction AlgorithmsPredictive Learning ModelsAntigens, Neoplasmcancer immunotherapycomputational pipelinedeep learningliquid biopsyneoantigen prediction

Identifiers

PMID41716398
PMCPMC12913462

What Socratic holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.